Home » Stocks » VSTM

Verastem, Inc. (VSTM)

Stock Price: $2.03 USD 0.07 (3.32%)
Updated Jan 27, 2021 12:06 PM EST - Market open
Market Cap 335.30M
Revenue (ttm) 91.63M
Net Income (ttm) -86.64M
Shares Out 169.51M
EPS (ttm) -0.67
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 27
Last Price $2.03
Previous Close $1.96
Change ($) 0.07
Change (%) 3.32%
Day's Open 1.93
Day's Range 1.87 - 2.07
Day's Volume 2,384,308
52-Week Range 1.11 - 4.20

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
The Motley Fool - 6 days ago

The biotech's chief medical officer has stepped down just two weeks after joining the company.

Business Wire - 1 week ago

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today an...

Seeking Alpha - 2 weeks ago

Verastem has recently raised non-dilutive capital to bring two assets into phase 2 trials. The company's lead asset has the potential to address around 30% of all cancers and be combined with ...

Business Wire - 2 weeks ago

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today an...

Business Wire - 3 weeks ago

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today an...

Business Wire - 3 weeks ago

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today an...

Business Wire - 1 month ago

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today an...

Zacks Investment Research - 1 month ago

Verastem (VSTM) initiates phase II registration-directed study of VS-6766 and defactinib in patients with recurrent low-grade serous ovarian cancer.

Business Wire - 1 month ago

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today an...

Business Wire - 2 months ago

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today re...

Business Wire - 2 months ago

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today an...

Zacks Investment Research - 3 months ago

Verastem (VSTM) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

Business Wire - 3 months ago

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today an...

Business Wire - 3 months ago

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today an...

Business Wire - 4 months ago

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today an...

Zacks Investment Research - 4 months ago

Investors need to pay close attention to Verastem (VSTM) stock based on the movements in the options market lately.

Business Wire - 4 months ago

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today an...

Business Wire - 4 months ago

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to developing and commercializing new medicines for patients batt...

The Motley Fool - 5 months ago

The biotech company reported second-quarter earnings and sold some drug development rights.

Business Wire - 5 months ago

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to developing and commercializing new medicines for patients batt...

Business Wire - 5 months ago

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today an...

Zacks Investment Research - 5 months ago

Verastem (VSTM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Alpha - 6 months ago

Verastem: A Growth Story In The Biotechnology Sector

Business Wire - 7 months ago

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to developing and commercializing new medicines for patients batt...

Zacks Investment Research - 8 months ago

Investors need to pay close attention to Verastem (VSTM) stock based on the movements in the options market lately.

The Motley Fool - 8 months ago

If this biotech is ever going to reward its shareholders, it will be via its pipeline candidates.

Zacks Investment Research - 8 months ago

Is (VSTM) Outperforming Other Medical Stocks This Year?

The Motley Fool - 8 months ago

Details from a clinical trial with the company's latest lead candidate weren't what investors had hoped for.

The Motley Fool - 9 months ago

Agenus, Dynavax Technologies, and Verastem Oncology could all be outstanding picks for risk-tolerant investors.

Other stocks mentioned: AGEN, DVAX
The Motley Fool - 9 months ago

Investors are excited about an upcoming conference call to discuss clinical data from patients with KRAS-mutation positive tumors.

Zacks Investment Research - 9 months ago

Verastem (VSTM) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.

Seeking Alpha - 9 months ago

Verastem Oncology: An Undervalued KRAS Oncology Play

The Motley Fool - 10 months ago

Healthcare bargain hunters can find good values in quality low-priced stocks.

Other stocks mentioned: AMGN, AMRX, MRTX, VKTX
Zacks Investment Research - 10 months ago

Is (VSTM) Outperforming Other Medical Stocks This Year?

Zacks Investment Research - 10 months ago

Verastem has been struggling lately, but the selling pressure may be coming to an end soon.

Zacks Investment Research - 10 months ago

As of late, it has definitely been a great time to be an investor in Verastem, Inc. (VSTM).

Seeking Alpha - 11 months ago

Verastem: Outlook For 2020-21

Seeking Alpha - 11 months ago

Verastem: Still Bullish After Chugai Pharmaceutical Deal

GuruFocus - 11 months ago

Billionaire investor Steven Cohen (Trades, Portfolio), head of Point72 Asset Management, disclosed earlier this week his firm established a new 14.91% stake in Verastem Inc.

Zacks Investment Research - 1 year ago

Verastem (VSTM) enters into an agreement with Chugai Pharmaceutical to gain worldwide rights to the latter's RAF/MEK inhibitor, CH5126766, for $3 million in upfront payment.

Zacks Investment Research - 1 year ago

Investors need to pay close attention to Verastem (VSTM) stock based on the movements in the options market lately.

Seeking Alpha - 1 year ago

Verastem: Earnings Beat And Executing 6-2-5 Plan Trigger Unjustified Sell-Off

Seeking Alpha - 1 year ago

Verastem, Inc. (VSTM) CEO Brian Stuglik on Q3 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Verastem (VSTM) delivered earnings and revenue surprises of 16.67% and -1.83%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Seeking Alpha - 1 year ago

Verastem Oncology's share price continues to flatline as we approach the end of 2019. The market appears to have branded COPIKTRA's launch as a dud.

Zacks Investment Research - 1 year ago

Verastem's (VSTM) Copiktra gets orphan drug designation from the FDA for use in the treatment of T-Cell lymphoma.

Seeking Alpha - 1 year ago

Verastem, Inc. (VSTM) CEO Brian Stuglik on Q2 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Verastem (VSTM) delivered earnings and revenue surprises of 2.04% and 41.13%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Seeking Alpha - 1 year ago

Verastem announced they out-licensed COPIKTRA to Sanofi Develop and Commercialize in emerging markets. Verastem will receive an upfront payment of $5M, plus milestones and royalties.

Zacks Investment Research - 1 year ago

Verastem (VSTM) presents encouraging data from an early-stage study evaluating its recently approved drug, Copiktra, for treating peripheral T-cell lymphoma.

About VSTM

Verastem, Inc., a biopharmaceutical company, focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma (FL) after at least two prior s... [Read more...]

Industry
Biotechnology
IPO Date
Jan 27, 2012
CEO
Brian Stuglik
Employees
135
Stock Exchange
NASDAQ
Ticker Symbol
VSTM
Full Company Profile

Financial Performance

In 2019, Verastem's revenue was $17.46 million, a decrease of -34.67% compared to the previous year's $26.72 million. Losses were -$149.21 million, 106.0% more than in 2018.

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for Verastem stock is "Buy." The 12-month stock price forecast is 3.83, which is an increase of 89.14% from the latest price.

Price Target
$3.83
(89.14% upside)
Analyst Consensus: Buy